Personalized Medicine Not Paying The Bills Yet; More Science Needed
Executive Summary
Though the promise of personalized medicine has been widely touted, firms focusing on targeted therapies and companion diagnostics are not getting much bang for their buck - yet
You may also be interested in...
Roche Makes Early Headway With Pharmaco-Diagnostics
As discussion of personalized medicine transitions from being a hot new topic to a predominant mentality for R&D, a lot of focus is on Roche to see how the diversified company leverages its dual footholds in the pharmaceutical and diagnostics worlds
Warfarin Dosing Issues Emerge In Early Results From Medco/Mayo Research
Nearly three-fourths of early patient participants in a warfarin research project appear to need non-standard dosing of the drug based on genetic screening, Medco reported during its analyst day presentation Nov. 16
Warfarin Label Change Falls Short of Recommending Genetic Testing
FDA took warfarin one step into the world of personalized medicine Aug. 16 with labeling changes that inform patients and doctors about the usefulness of genetic testing before beginning therapy with the blood thinner